Viemed Healthcare, Inc. (VMD)

LAFAYETTE, LA / ACCESS Newswire / February 24, 2026 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, today announced that it will host its Year End 2025 earnings conference call on Thursday, March 5, 2026, at 11:00 a.m. ET. Interested parties may participate in the call by dialing: 877-407-6176 (US Toll-Free) +1 201-689-8451 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=hp8iUwVS Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com.

Viemed Healthcare is reiterated as a 'Buy' due to robust revenue, earnings, and cash flow growth, alongside an expanding patient base. Q1 and Q2 2025 saw strong organic growth, with Lehan's acquisition quickly accretive and driving further patient count gains. Despite recently trimming FY2025 top-line guidance, VMD's valuation remains compelling with P/E, P/S, and P/B well below 5-year averages.

Dallas, Texas--(Newsfile Corp. - January 6, 2026) - Viemed Healthcare, Inc. (NASDAQ: VMD). Stonegate Capital Partners initiates their coverage on Viemed Healthcare, Inc. (NASDAQ: VMD).

Viemed Healthcare, Inc. ( VMD ) Q3 2025 Earnings Call November 6, 2025 11:00 AM EST Company Participants Trae Fitzgerald - Chief Financial Officer Casey Hoyt - CEO & Director Todd Zehnder - COO & Director Conference Call Participants Doug Cooper - Beacon Securities Limited, Research Division Robert Lynch Ilya Zubkov - Freedom Broker, Research Division Presentation Operator Greetings, and welcome to the Viemed Healthcare Third Quarter 2025 Earnings Call. [Operator Instructions] Please note, this conference is being recorded.

LAFAYETTE, LA / ACCESS Newswire / November 5, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today that it has reported its financial results for the three and nine months ended September 30, 2025. Operational highlights (all dollar amounts are USD): Net revenues for the quarter ended September 30, 2025 were $71.9 million, setting a Company record, representing an increase of $13.9 million, or 24.0%, over net revenues reported for the comparable quarter ended September 30, 2024.

LAFAYETTE, LA / ACCESS Newswire / October 21, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it will host its Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025, at 11:00 a.m. ET. Interested parties may participate in the call by dialing: (877) 407-6176 (US Toll-Free) +1 (201) 689-8451 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=asCOlSnC Following the live call, a replay will be available in the Investor Relations section of the Company's website at https://www.viemed.com.

LAFAYETTE, LA / ACCESS Newswire / September 23, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader of in-home, technology-enabled post-acute respiratory care, today announced that it has completed all repurchases authorized under its previously announced share repurchase program. On June 9, 2025, the Company announced that its Board of Directors had authorized the repurchase of up to 1,976,441 common shares, representing approximately 5% of the total issued and outstanding shares at the time of authorization.

Viemed Healthcare, Inc. (NASDAQ:VMD ) Q2 2025 Earnings Conference Call August 7, 2025 11:00 AM ET Company Participants Casey Hoyt - CEO & Director Trae Paul Fitzgerald - Chief Financial Officer William Todd Zehnder - COO & Director Conference Call Participants Ilya Zubkov - Freedom Broker, Research Division Ryan M. Langston - TD Cowen, Research Division Operator Greetings, and welcome to the Viemed Healthcare Second Quarter 2025 Earnings Call.

Viemed (VMD) Q2 Revenue Rises 15%

LAFAYETTE, LA / ACCESS Newswire / August 6, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced today that it has reported its financial results for the three and six months ended June 30, 2025. Operational highlights (all dollar amounts are USD; comparisons are to the period ended June 30, 2024 unless otherwise noted): Net revenues for the quarter ended June 30, 2025 were $63.1 million, setting another Company record, representing an increase of $8.1 million, or 14.7%, over net revenues reported for the comparable quarter ended June 30, 2024.

LAFAYETTE, LA / ACCESS Newswire / July 22, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, today announced that it will host its Second Quarter 2025 Earnings Conference Call on Thursday, August 7, 2025, at 11:00 a.m. EDT. Interested parties may participate in the call by dialing: (877) 407-6176 (US Toll-Free) +1 (201) 689-8451 (International) Live Audio Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=4jnXGdPH Following the live call, a replay will be available in the Investor Relations section of the Company's website at www.viemed.com.

LAFAYETTE, LA / ACCESS Newswire / July 2, 2025 / Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has completed the previously disclosed acquisition of Illinois-based Lehan's Medical Equipment ("Lehan") for a base purchase price of $26 million, subject to customary adjustments, plus estimated contingent payments of $2.2 million. "We are pleased to close the acquisition of Lehan and bring this talented and highly motivated team into the Viemed family," said Viemed Chief Executive Officer Casey Hoyt.

Viemed Healthcare, Inc. (NASDAQ:VMD ) Q1 2025 Earnings Conference Call May 8, 2025 11:00 AM ET Company Participants Casey Hoyt – Chief Executive Officer Trae Fitzgerald – Chief Financial Officer Todd Zehnder – Chief Operating Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Ryan Langston – TD Cowen Andrew Rem – Odinson Partners Operator Good day, ladies and gentlemen, and welcome to the Viemed Healthcare First Quarter 2025 Earnings Call. [Operator Instructions] At this time, it is my pleasure to turn the floor over to your host, Trae Fitzgerald, CFO.

LAFAYETTE, La., May 07, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it has reported its financial results for the three months ended March 31, 2025, and updated guidance for the full year ending December 31, 2025.

LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has entered into a definitive agreement to acquire Illinois-based Lehan's Medical Equipment (“Lehan”), a healthcare company offering home medical equipment with specialties in respiratory care and women's health.

DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particularly for applications such as patient recruitment and site identification, helps to reduce the workload for researchers and investigators. These factors contribute significantly to the growing adoption of analytics across the life sciences industry. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653 Browse in-depth TOC on "Life Science Analytics Market" 100 - Tables50 - Figures500 - Pages By Based on type, the life science analytics services market is categorized into two main types: managed services and professional services. In 2024, the managed services segment held the largest share of the life science analytics market. This significant share is largely due to the increasing demand for advanced insights, the need for cost-effective drug development, technological advancements in the industry, and the necessity for ongoing support in strategic decision-making. These factors make outsourcing analytics and consulting more attractive for life science companies. Leading companies in the field offer consulting services that leverage data and analytics to evaluate opportunities, design analytics strategies, and implement appropriate technology solutions. For instance, in May 2023, SAS Institute (US) partnered with HTEC (US) to deliver strategic analytics consulting services across various sectors, including life sciences and healthcare. By Based on applications, The life science analytics market is divided into several applications, including research & development, commercial analytics, regulatory compliance, manufacturing and supply chain optimization, and safety. In 2024, the research & development segment held the largest share of this market. This significant share is mainly due to its capacity to accelerate drug discovery, optimize clinical trials, and improve research accuracy through advanced data analysis and AI-driven insights. Additionally, factors such as increasing R&D expenditure in the pharmaceutical and biopharmaceutical sectors, a rise in patent expirations and declining drug pipelines, and a growing focus on personalized medicine and precision therapeutics are further driving growth in this segment. By geography, the life science analytics market is divided into five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to experience significant growth, with a noticeable annual growth rate during the forecast period. Key factors driving the expansion of life science analytics solutions in this region include a gradual shift towards adopting advanced technologies such as automation, artificial intelligence (AI), and machine learning (ML). Additionally, rising investments are attracting new market players, and the presence of leading educational institutions and research centers in Asia Pacific is fostering scientific innovation and technological advancement. Furthermore, increased direct investments from pharmaceutical and biotechnology companies in Europe and North America are anticipated to boost the adoption of life science analytics solutions in Asia. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653 Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US), Microsoft (US), MaxisIT (US), ExlService Holdings (US), Inovalon (US), CitiusTech (US), Saama (US), Axtria (US), Clarivate (UK), ThoughtSphere (US), ThoughtSpot (US), Salesforce (US), Google LLC (US), Amazon Web Services, Inc. (US), Veeva Systems (US), Elsevier (Netherlands), and Komodo Health, Inc. (US) are the major players in this market. These companies mainly focus on strategies such as acquisitions, collaborations, partnerships, expansion, and product launches and updates to remain competitive and further increase their share in the market. ORACLE (US): Oracle (US) is a leading company in life science analytics worldwide. The company offers analytics software and services for various applications, including research & development, commercialization, and more. Oracle is committed to continuously updating its products to meet customer expectations. Additionally, the company invests in expanding its solutions through partnerships and collaborations, ensuring tailored solutions for its users. In March 2025, Oracle partnered with Huntsville Hospital Health System (US) to standardize its Oracle Health Foundation electronic health record system across all facilities. This collaboration aims to provide consistent, high-quality care and a unified experience for both patients and providers as they move between different locations. With a broad customer base and a significant geographic presence, Oracle is a critical player in various IT software, hardware, and service markets, including life science analytics. MERATIVE (US): Merative (US) is another leading player in the life science analytics market. The company offers a comprehensive suite of informatics products and services tailored for life science analytics. By leveraging advanced technologies such as AI and ML, Merative enhances the accuracy and efficiency of evidence analysis. Its strong brand recognition and extensive product portfolio have significantly contributed to its success. Merative serves various sectors, including life science systems, clinical trial sponsors, and the medical device manufacturing industry. Additionally, the company has established offices across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. SAS INSTITUTE INC. (US) SAS Institute Inc. (US) is a company that specializes in analytics software and services. It offers a wide range of solutions, including advanced analytics, business intelligence, cloud analytics, customer intelligence, data operations, data management, decision management, fraud and security intelligence, in-memory analytics, performance management, risk management, and supply chain management. These solutions enable organizations to access, manage, analyze, and report on data to support informed decision-making. SAS Institute serves various industries, including communications, education, financial services, government, health insurance, healthcare, hospitality, insurance, life sciences, manufacturing, media, oil and gas, retail, travel and transportation, and utilities. Through its Life Sciences industry segment, the company also provides specialized analytics solutions for the life sciences sector. By leveraging AI and analytics driven by fast and relevant data, SAS aims to propel innovation in health and life sciences. The company supports customers in 146 countries across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. More than 82,000 business, government, and university sites utilize SAS OnDemand for Academics. For more information, Inquire Now! Related Reports: Healthcare Analytics Market Healthcare BPO Market Healthcare IT Market Artificial Intelligence (AI) in Healthcare Market Healthcare Data Monetization Market Get access to the latest updates on Life Science Analytics Companies and Life Science Analytics Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg